A joint initiative by the Associació Catalana d´Universitats Públiques (ACUP) and Obra Social la Caixa, RecerCaixa has earmarked €9m for the period 2010-2014 to finance research projects selected for their scientific quality. The first twenty, which were chosen from 461 hopefuls, focus on health sciences, particularly public health, and social sciences to do with education and immigration.
Pau’s project goes deep into the new pharmacological concept of light-controlled drugs (photopharmacology), including how to regulate their effectiveness and the spatial and temporal distribution of their physiological effects. It’s hoped that the results of this study will be relevant to personalised medicine and the development of patient-specific therapies.
This is the second major project involving Pau who, alongside Fausto Sanz, heads IBEC’s Nanoprobes and Nanoswitches group. In January the collaborative project Single Molecule Activation and Computing (FOCUS), in which he is a partner, was awarded funding by the EU for its work on building a next generation of biologically inspired molecular devices based on new photonic tools.
For more about RecerCaixa visit www.recercaixa.cat.
This story was covered today in La Vanguardia:
http://edicionimpresa.lavanguardia.es/premium/epaper/20110222/54118430828.html
